Prothya Biosolutions: Clinical Trials

10 trials sponsored by Prothya Biosolutions, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 2 active not recruiting, 2 terminated. 10 Phase 2, 4 Phase 3, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 210Completed 6, Active not recruiting 2, Terminated 2
Phase 34Completed 2, Active not recruiting 1, Terminated 1
Phase 12Completed 2

Follow Prothya Biosolutions: new trials by email

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Dose-Response in PD and Safety of Cofact Under VKA Anticoagulation
Cofact - Healthy Volunteers
Phase 1 / Phase 2CompletedProthya Biosolutions692021-11-122024-04-08
Add-on Intravenous Immunoglobulins in Early Myositis
Immune Globulin Intravenous (Human), Placebo - Inflammatory Myopathy, Idiopathic, Dermatomyositis
Phase 2 / Phase 3Active not recruitingAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)442021-09-132026-02-27
Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study)
Convalescent plasma - COVID-19
Phase 2 / Phase 3TerminatedErasmus Medical Center862020-04-082022-04-01
Apotransferrin in Patients With β-thalassemia
human apotransferrin - β-thalassemia Intermedia
Phase 2TerminatedProthya Biosolutions102019-03-212022-08-15
Apotransferrin in Atransferrinemia
Human apotransferrin - Congenital Atransferrinemia
Phase 2Active not recruitingProthya Biosolutions52010-12-012026-09-16
C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema
C1 inhibitor concentrate (C1-esteraseremmer-N) - Angioedema
Phase 2 / Phase 3CompletedProthya Biosolutions62006-11-012009-05-04
Kinetics, Efficacy and Safety of C1-Esteraseremmer-N
C1 inhibitor concentrate - Hereditary Angioedema Type I, Angioneurotic Edema
Phase 2CompletedProthya Biosolutions122005-09-012009-05-04
Succinylated Human Serum Albumin (Suc-HSA) for HIV-1 Infection
succinylated human serum albumin - HIV Infections
Phase 1 / Phase 2CompletedInternational Antiviral Therapy Evaluation Center62005-08-012007-04-24
Study on Mannan Binding Lectin (MBL) Substitution in MBL-Deficient Children With Chemotherapy-Induced Neutropenia
Mannan Binding Lectin (MBL), Mannan Binding Lectin - MBL-Deficient, Neutropenia
Phase 2CompletedProthya Biosolutions122004-04-012007-08-30
Kinetics, Efficacy and Safety of IVIG-L in Hypogammaglobulinemia Patients
IVIG-L - Hypogammaglobulinemia
Phase 2 / Phase 3CompletedProthya Biosolutions152001-05-012007-04-19

Conditions studied

Angioedema (2)  ·  Hereditary Angioedema Types I and II (2)  ·  Acquired angioedema (1)  ·  Agammaglobulinemia (1)  ·  Anemia (1)  ·  Antisynthetase syndrome (1)  ·  COVID-19 (1)  ·  Congenital atransferrinemia (1)  ·  Dermatomyositis (1)  ·  HIV Infections (1)  ·  Iron Overload (1)  ·  Myositis (1)  ·  Neutropenia (1)  ·  Polymyositis (1)

Interventions

Immunoglobulins, Intravenous (1)  ·  Mannose-Binding Lectin (1)  ·  Sodium Chloride (1)  ·  prothrombin complex concentrates (1)

Countries

Netherlands (9)  ·  Germany (1)  ·  Italy (1)  ·  Spain (1)

Top investigators

M. M. Levi, Prof. Dr. (2)  ·  Alberto Piperno, MD, PhD (1)  ·  Bart Biemond, MD, PhD (1)  ·  Bart Rijnders, MD, PhD (1)  ·  H N Caron (1)  ·  Jan Prins, MD PhD (1)  ·  Joep MA Lange, MD PhD (1)  ·  Katja Moser, MD (1)  ·  Raffaella Mariani, MD, PhD (1)  ·  Salah Hadi, MD (1)  ·  T W Kuijpers, MD, PdD (1)  ·  Thomas Bodewes, MD (1)

Results publications

PMID 33044747, PMID 34013969, PMID 36734509, PMID 37162745